Burns J W & Co INC Position in Bristol (BMY) Trimmed as Stock Value Rose

September 16, 2018 - By Jack Shaw

Bristol-Myers Squibb Company (NYSE:BMY) LogoInvestors sentiment decreased to 0.78 in Q2 2018. Its down 0.05, from 0.83 in 2018Q1. It dropped, as 94 investors sold BMY shares while 550 reduced holdings. 108 funds opened positions while 396 raised stakes. 1.14 billion shares or 1.65% more from 1.12 billion shares in 2018Q1 were reported. United Svcs Automobile Association has 0.01% invested in Bristol-Myers Squibb Company (NYSE:BMY) for 131,127 shares. Moreover, Woodley Farra Manion Mgmt has 0.03% invested in Bristol-Myers Squibb Company (NYSE:BMY). Carnegie Asset Mngmt Ltd Llc has invested 0.56% in Bristol-Myers Squibb Company (NYSE:BMY). London Of Virginia accumulated 954,292 shares. Orbimed Advsrs Limited accumulated 2.38M shares. Signalpoint Asset Management Limited Liability reported 5,945 shares. Clough Capital LP holds 0.72% or 146,660 shares. New York-based Neville Rodie & Shaw Inc has invested 0.52% in Bristol-Myers Squibb Company (NYSE:BMY). Arete Wealth Advisors Limited Liability Company invested in 20,211 shares or 0.27% of the stock. State Of Tennessee Treasury Department, Tennessee-based fund reported 1.23 million shares. Lvm Cap Ltd Mi holds 0.18% in Bristol-Myers Squibb Company (NYSE:BMY) or 13,437 shares. Btim owns 0.01% invested in Bristol-Myers Squibb Company (NYSE:BMY) for 18,208 shares. Twin Mgmt invested in 197,080 shares or 0.55% of the stock. Blackhill Capital, a New Jersey-based fund reported 436,945 shares. Tower Bridge Advsrs invested in 130,044 shares or 0% of the stock.

Since April 30, 2018, it had 1 buy, and 0 selling transactions for $249,948 activity.

Burns J W & Co Inc decreased its stake in Bristol (BMY) by 46.05% based on its latest 2018Q2 regulatory filing with the SEC. Burns J W & Co Inc sold 65,024 shares as the company’s stock rose 12.85% with the market. The institutional investor held 76,176 shares of the major pharmaceuticals company at the end of 2018Q2, valued at $4.22 million, down from 141,200 at the end of the previous reported quarter. Burns J W & Co Inc who had been investing in Bristol for a number of months, seems to be less bullish one the $99.04 billion market cap company. The stock decreased 0.16% or $0.1 during the last trading session, reaching $60.69. About 3.89M shares traded. Bristol-Myers Squibb Company (NYSE:BMY) has declined 4.27% since September 16, 2017 and is downtrending. It has underperformed by 19.89% the S&P500.

Analysts await Bristol-Myers Squibb Company (NYSE:BMY) to report earnings on October, 25. They expect $0.89 EPS, up 18.67 % or $0.14 from last year’s $0.75 per share. BMY’s profit will be $1.45 billion for 17.05 P/E if the $0.89 EPS becomes a reality. After $1.01 actual EPS reported by Bristol-Myers Squibb Company for the previous quarter, Wall Street now forecasts -11.88 % negative EPS growth.

More notable recent Bristol-Myers Squibb Company (NYSE:BMY) news were published by: Streetinsider.com which released: “Natera (NTRA) Enters Agreement with Bristol-Myers (BMY) for Signatera ctDNA Assay” on September 13, 2018, also Seekingalpha.com with their article: “Bristol-Myers Squibb Company (BMY) CEO Giovanni Caforio Presents at Morgan Stanley 16th Annual Global …” published on September 13, 2018, 247Wallst.com published: “Short Sellers Back Off Major Pharma Stocks” on September 13, 2018. More interesting news about Bristol-Myers Squibb Company (NYSE:BMY) were released by: Seekingalpha.com and their article: “Why Yervoy’s Resurgence Will Gain Momentum” published on August 27, 2018 as well as Seekingalpha.com‘s news article titled: “Bristol-Myers Squibb’s TYK2 inhibitor successful in mid-stage psoriasis study” with publication date: September 12, 2018.

Bristol-Myers Squibb Company (NYSE:BMY) Ratings Coverage

Among 11 analysts covering Bristol Myers (NYSE:BMY), 2 have Buy rating, 0 Sell and 9 Hold. Therefore 18% are positive. Bristol Myers had 14 analyst reports since March 20, 2018 according to SRatingsIntel. The firm earned “Neutral” rating on Tuesday, April 17 by Bank of America. The firm has “Market Perform” rating by BMO Capital Markets given on Friday, April 27. The rating was maintained by BMO Capital Markets on Wednesday, April 18 with “Underperform”. As per Tuesday, April 17, the company rating was downgraded by Morgan Stanley. The company was maintained on Friday, April 13 by Jefferies. The rating was maintained by Guggenheim on Tuesday, April 17 with “Buy”. On Friday, April 20 the stock rating was maintained by Cowen & Co with “Hold”. The stock has “Market Perform” rating by BMO Capital Markets on Monday, July 23. As per Friday, March 23, the company rating was maintained by Jefferies. The stock of Bristol-Myers Squibb Company (NYSE:BMY) earned “Hold” rating by UBS on Monday, May 21.

Bristol-Myers Squibb Company (NYSE:BMY) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.